Licensing moves towards early-stage assets in 2021
Danni Yin · 01/14/2022
Early-stage assets made up half of the licensing deals in 2021, up 10% from the previous year.
READ MORE
2021 wraps up with multi-billion dollar deals
Minhua Chu · 01/07/2022
In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms.
READ MORE
Hansoh’s siRNA therapeutics deals stand out in October
Minhua Chu · 11/19/2021
Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics.
READ MORE
September sees the most licensing deals of the year so far
Minhua Chu · 10/28/2021
Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals.
READ MORE
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement